Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nikos Kentepozidis"'
Autor:
Dimitris Mavroudis, Nikos Kentepozidis, John Souglakos, Charalambos Christofillakis, Athanasios Kotsakis, Vassilis Georgoulias, Stelios Giassas, George Samonis, Athanasios Karampeazis, M. Agelidou, Alexandra Voutsina, Lambros Vamvakas, Sofia Agelaki, Pavlos Papakotoulas, Ageliki Rapti
Publikováno v:
Cancer. 119:2754-2764
BACKGROUND: In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic non–small cell lung cancer (NSCLC). METHODS: Patients with stage IIIB/IV NSCLC who progressed after first-line or second-line trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33ef7eaf8c6a47853703909141143ba9
https://doi.org/10.1002/cncr.28132
https://doi.org/10.1002/cncr.28132
Autor:
Michalis V. Karamouzis, Georgia Milaki, Stavros D. Peroukidis, Nikos Pistalmatzian, Ioannis Varthalitis, Dimitrios Mavroudis, Charalambos Andreadis, Sophia Stamatopoulou, Nikos Androulakis, Antonios Agorastos, H. P. Kalofonos, Aristotle Bamias, Nikos Kentepozidis, Vasiliki Bozionelou, Athanasios Papatsoris, Kimon Tzannis, Meletios A. Dimopoulos, Konstantinos Koutsoukos, Konstantinos Stravodimos, Iliada Bompolaki
Publikováno v:
Clinical genitourinary cancer. 14(2)
Background Advanced urothelial cancer (AUCa) is associated with poor long-term survival. Two major concerns are related to nonexposure to cisplatin-based chemotherapy and poor outcome after relapse. Our purpose was to record patterns of practice in A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e02824d8f1fab61135432ff1afc35e09
https://pubmed.ncbi.nlm.nih.gov/26437909
https://pubmed.ncbi.nlm.nih.gov/26437909
Autor:
Athanasios, Karampeazis, Alexandra, Voutsina, John, Souglakos, Nikos, Kentepozidis, Stelios, Giassas, Charalambos, Christofillakis, Athanasios, Kotsakis, Pavlos, Papakotoulas, Ageliki, Rapti, Maria, Agelidou, Sofia, Agelaki, Lambros, Vamvakas, George, Samonis, Dimitris, Mavroudis, Vassilis, Georgoulias
Publikováno v:
Cancer. 119(15)
In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic non-small cell lung cancer (NSCLC).Patients with stage IIIB/IV NSCLC who progressed after first-line or second-line treatment were randomized to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::24ba0c3bd68c10411c016c62938b6caf
https://pubmed.ncbi.nlm.nih.gov/23661337
https://pubmed.ncbi.nlm.nih.gov/23661337